Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

Lundbeck unveils migraine data for eptinezumab at international congress

by PharmaTimes
0 Comments
0 Mins
New phase 4 results show sustained symptom relief and improved patient outcomes New phase 4 results show sustained symptom relief and improved patient outcomes
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
18 Quacks caught during Telangana Medical Council raids
Next Post
cost self breast examination model
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago